SavedAdd your journal

Journals / Marmara Medical Journal / 2026 / Volume: 36 Issue: 1

The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma

Ayse Uysal(FIRAT UNIVERSITY)0000-0002-5581-8104
Mehmet Ali Erkurt(INONU UNIVERSITY)0000-0002-3285-417X
Irfan Kuru(INONU UNIVERSITY)0000-0001-6126-0816
Emin Kaya(INONU UNIVERSITY)0000-0001-8605-8497
Ilhami Berber(INONU UNIVERSITY)0000-0003-3312-8476
Ahmet Sarıcı(Malatya Training and Research Hospital)0000-0002-5916-0119
Soykan Bıcım(INONU UNIVERSITY)0000-0001-7498-344X
Ahmet Kaya(INONU UNIVERSITY)0000-0002-0742-4629
Emine Hıdayet(INONU UNIVERSITY)0000-0003-3121-7387
Pages
—
Publication Date
2023-01-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACT Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ μL in the peripheral blood (PB) on the 4th day of mobilization.
📊
Key Findings & Data:Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included.
💡
Conclusion & Impact:Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Apheresis · Stem cell · Mobilization

Abstract

ABSTRACT Objective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiple myeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of <15/ μL in the peripheral blood (PB) on the 4th day of mobilization. Patients and Methods: Thirty-five patients who were administered plerixafor on the 4th day after granulocyte colony-stimulating factor (G-CSF) alone for stem cell mobilization between January 2020 and November 2021 were included. CD34+ stem cell counts in PB before and after plerixafor, the amount of CD34+ stem cells collected, and the outcome of transplantation was examined. Results: The median CD34+ cell count in PB on the 4th day was 5.2/μL (0.1-13.4), which was determined to increase 206.6-fold (31.57- 49347) to 924.80 /μL (295.00-5056) following the administration of plerixafor on the 5th day (Z=-5.160; r= – 872.2; p<0.0001). The number of apheresis sessions was 1 in all patients. The median collected CD34+ cell count was 5.90x106/kg (2.70x106-14.4x106). Conclusion: The use of preemptive plerixafor shows that it is an effective mobilization method by increasing the rate of stem cell collection at an effective dose and reducing the mobilization time/apheresis sessions.

🔖

Cite This Article

Uysal, A., Erkurt, M. A., Kuru, I., Kaya, E., Berber, I., Sarıcı, A., Bıcım, S., Kaya, A., Hıdayet, E. (2023). The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma. Marmara Medical Journal, Volume: 36 Issue: 1. https://doi.org/10.5472/marumj.1244684

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (24)

  1. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219-34. doi: 10.1038/ bmt.2009.141
  2. Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47:906-23. doi: 10.1038/bmt.2012.66
  3. Arora S, Majhail NS, Liu H. Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary era. Clin Lymphoma Myeloma Leuk 2019;19:200-5. doi: 10.1016/j.clml.2018.12.010
  4. Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014;49:865-72. doi: 10.1038/bmt.2014.39
  5. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol of Blood Marrow Transplant 2014;20:295-308. doi: 10.1016/j. bbmt.2013.10.013
  6. Farina L, Spina F, Guidetti A, et al. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocytecolony- stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leukemia Lymphoma 2014;55:331-6. doi: 10.3109/10428.194.2013.802783
  7. Ataca Atilla P, Bakanay Ozturk SM, Demirer T. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfusion Apher Sci 2017;56:190- 8. doi: 10.1016/j.transci.2016.11.005
  8. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-9. doi: 10.1016/j. bbmt.2009.11.012
  9. Lee JL, Kim SB, Lee GW, et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apher Sci 2003;29:29-37. doi: 10.1016/s1473- 0502(03)00097-1
  10. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008;22:1282-4. doi: 10.1038/ sj.leu.2405100
  11. Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012;47:342-51. doi: 10.1038/bmt.2011.82
  12. Shah EE, Young RP, Wong SW, et al. Impact of plerixafor use at different peripheral blood cd34(+) thresholds on autologous stem cell collection in patients with multiple myeloma. Blood Marrow Transplant 2020;26:876-83. doi: 10.1016/j. bbmt.2019.11.024
  13. Douglas KW, Gilleece M, Hayden P, et al. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher 2018;33:46-59. doi: 10.1002/jca.21563
  14. Keating GM. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 2011;71:1623-47. doi: 10.2165/11206.040.000000000- 00000
  15. Cooper DL, Medoff E, Patel N, et al. Autologous stem cell mobilization in the age of plerixafor. Clin Lymphoma Myeloma Leuk 2016;16:411-6. doi: 10.1016/j.clml.2016.04.007
  16. Spoerl S, Peter R, Wäscher D, et al. Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Transfusion 2017;57:115-21. doi: 10.1111/trf.13883
  17. Gambell P, Herbert K, Dickinson M, et al. Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield:an analysis of more than 1,000 collections. Blood Marrow Transplant 2012;18:763-72. doi: 10.1016/j.bbmt.2011.10.002
  18. Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA. Identification of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization. Transfusion 2011;51:587-90. doi: 10.1111/j.1537-2995.2010.02891.x
  19. Sancho JM, Morgades M, Grifols JR, et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy 2012;14:823-9. doi: 10.3109/14653.249.2012.681042
  20. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-9. doi: 10.1038/bmt.2010.78
  21. Solá C, Maroto P, Salazar R, et al. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): The CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology (Amsterdam, Netherlands) 1999;4:195-209. doi: 10.1080/10245.332.1999.11746443
  22. Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher 2017;32:224-34. doi: 10.1002/jca.21496
  23. Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Blood Marrow Transplant 2013;19:87-93. doi: 10.1016/j. bbmt.2012.08.010
  24. Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and costbenefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012;52:55-62. doi: 10.1111/j.1537-2995.2011.03206.x